Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum extract is an extract derived from the probiotic bacterium *Lactobacillus plantarum*. The ethyl acetate extract from the specific strain ATCC 14917 has been studied for its potential anti-cancer properties. Research has shown that this extract can selectively induce apoptosis (programmed cell death) in human colorectal cancer cells (Caco-2) while leaving healthy cells unharmed. The mechanism of action involves the activation of the intrinsic apoptosis pathway, characterized by the downregulation of anti-apoptotic proteins like Bcl-2 and Bcl-xL, and the upregulation of pro-apoptotic proteins such as Bak, Bad, and Bax. This leads to an increase in the activity of caspases, specifically caspase-3 and caspase-9, ultimately causing cancer cell death. [14] These findings suggest that extracts from *Lactobacillus plantarum* could be considered for development as targeted anti-cancer treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus plantarum extract.